SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

Inicio・Lista de Acciones・Bayer AG

Bayer AG

Abierto

SectorFinanzas

38.61 0.44

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

38.39

Máximo

38.78

Métricas clave
By Trading Economics
Ingresos	6.5B 2.8B
Ventas	2B 13B
BPA	2.812
Rentabilidad por dividendo	0.29
Margen de beneficios	20.612
Empleados	87,757
EBITDA	2.3B 4.4B

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+25.11% upside

Dividendos
By Dow Jones
Rentabilidad por dividendo Media del Sector	0.29% 4.64%
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	737M 37B
Apertura anterior	38.17
Cierre anterior	38.61

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

91 / 438 Clasificación en Finance

Bayer AG Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 may 2026, 11:24 UTC

Ganancias

Principales Movimientos del Mercado

Bayer Shares Climb After Earnings Beat Expectations

12 may 2026, 06:10 UTC

Ganancias

Bayer Net Profit Surges Driven by Growth in Agricultural Division

6 may 2026, 10:51 UTC

Adquisiciones, fusiones, absorciones

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion -- Update

6 may 2026, 07:01 UTC

Adquisiciones, fusiones, absorciones

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion

12 may 2026, 12:05 UTC

Acciones populares

Stocks to Watch: GameStop, Venture Global, Wendy's, Hims & Hers -- WSJ

12 may 2026, 10:51 UTC

Acciones populares

Stocks to Watch: GameStop, Venture Global, Hims & Hers, GoPro -- WSJ

12 may 2026, 09:08 UTC

Acciones populares

Stocks to Watch: Venture Global, Hims & Hers, GoPro -- WSJ

12 may 2026, 05:38 UTC

Ganancias

Bayer Backs 2026 Outlook Adjusted for Currency

12 may 2026, 05:36 UTC

Ganancias

Bayer 1Q Consumer Health Sales Grew 5.3%, Adjusted for Currency, Portfolio Changes

12 may 2026, 05:36 UTC

Ganancias

Bayer 1Q Pharma Sales Fell 0.5%, Adjusted for Currency, Portfolio Changes

12 may 2026, 05:36 UTC

Ganancias

Bayer 1Q Crop Science Sales Grew 6.8%, Adjusted for Currency, Portfolio Changes

12 may 2026, 05:35 UTC

Ganancias

Bayer 1Q Adj EPS EUR2.71

12 may 2026, 05:34 UTC

Ganancias

Analysts Saw Bayer 1Q Net Profit From Continuing Operations at EUR1.60B

12 may 2026, 05:34 UTC

Ganancias

Analysts Saw Bayer 1Q Ebitda Before Special Items at EUR3.93B

12 may 2026, 05:34 UTC

Ganancias

Analysts Saw Bayer 1Q Sales at EUR13.42B

12 may 2026, 05:34 UTC

Ganancias

Bayer 1Q Sales Grew 4.1% When Adjusted for Currency, Portfolio Changes

12 may 2026, 05:33 UTC

Ganancias

Bayer 1Q EBIT EUR3.53B

12 may 2026, 05:32 UTC

Ganancias

Bayer 1Q Ebitda Before Special Items EUR4.45B

12 may 2026, 05:32 UTC

Ganancias

Bayer 1Q Net Pft EUR2.76B

12 may 2026, 05:31 UTC

Ganancias

Bayer 1Q Sales EUR13.405B

12 may 2026, 05:31 UTC

Ganancias

Bayer Backs 2026 View

6 may 2026, 06:34 UTC

Adquisiciones, fusiones, absorciones

Bayer: Perfuse's Lead Program Is Treatment for Glaucoma and Diabetic Retinopathy

6 may 2026, 06:33 UTC

Adquisiciones, fusiones, absorciones

Bayer: Acquisition Aims to Complement Ophthalmology Pipeline

6 may 2026, 06:33 UTC

Adquisiciones, fusiones, absorciones

Bayer: Additional Payments Subject to Development, Regulatory, and Commercial Milestones

6 may 2026, 06:32 UTC

Adquisiciones, fusiones, absorciones

Bayer to Pay $300M Upfront

6 may 2026, 06:32 UTC

Adquisiciones, fusiones, absorciones

Bayer to Buy Perfuse Therapeutics for Up to $2.45B

6 may 2026, 06:31 UTC

Adquisiciones, fusiones, absorciones

Bayer to Buy Perfuse Therapeutics

6 may 2026, 06:30 UTC

Adquisiciones, fusiones, absorciones

Bayer To Acquire Perfuse Therapeutics To Complement Ophthalmology Pipeline >BAYN.XE

8 abr 2026, 14:41 UTC

Ganancias

Buy Johnson & Johnson Stock Ahead of Earnings, Analyst Says. The Gains Can Continue. -- Barrons.com

1 abr 2026, 14:24 UTC

Charlas de Mercado

Bayer Pharma Head Touts Healthiest Pipeline in Company's History -- Market Talk

Comparación entre iguales

Cambio de precio

Bayer AG previsión

Precio Objetivo

By TipRanks

25.11% repunte

Estimación a 12 Meses

Media 48.18 EUR 25.11%

Máximo 56 EUR

Mínimo 25 EUR

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bayer AG Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

Comprar

Mantener

Vender

De acuerdo con 12 analistas que ofrecen calificaciones bursátiles a para Bayer AG Dist en los últimos 3 meses.

Sentimiento

By Acuity

91 / 438 Clasificación en Finanzas

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.